Clinical Trials Directory

Trials / Terminated

TerminatedNCT02717013

The Effect of HMB Supplementation on Adipose Tissue Inflammation and Metabolism

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
10 (actual)
Sponsor
Metabolic Technologies Inc. · Industry
Sex
Male
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

This study will determine the effects of supplementing beta-hydroxy-beta-methylbutyrate (HMB) on body composition and strength changes during weight loss. When overweight and obese persons lose weight, and in particular in conjunction with dietary restrictions, muscle, bone mass, and muscle strength are also lost. HMB has been shown to preserve muscle mass and strength, and it is thought that HMB may also preserve muscle, bone, and strength during weight-loss.

Detailed description

Forty obese men (BMI 35-40 kg/m2,18-40 years of age) will be randomly assigned to one of four treatment interventions: 1) Calorie restricted; 2) Calorie restricted and HMB supplemented; 3) No calorie restriction; and 4) No calorie restriction and HMB-supplemented. Over the 8 week interventional period the calorie restricted group is expected to lose 3-5% of initial body weight. Anthropometric measures will be taken weekly, and dual energy x-ray absorptiometry (DXA) body composition and strength will be measured before and after 8-weeks of intervention. Blood and urine will be collected and analyzed at 0, 4, and 8 weeks. Additionally Dietary records and questionnaires concerning quality of life will be administered, and activity will be assessed using questionnaires and pedometers. Muscle biopsies will be taken before and after the 8-week study.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTPlaceboPlacebo capsules containing calcium lactate similar to the HMB capsules.
DIETARY_SUPPLEMENTHMBHMB capsules supplying 3 grams per day of calcium beta-hydroxyl-beta-methylbutyrate.

Timeline

Start date
2016-03-01
Primary completion
2017-02-01
Completion
2017-02-01
First posted
2016-03-23
Last updated
2017-03-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02717013. Inclusion in this directory is not an endorsement.